Vaccine manufacturers’ strategies to expand their global manufacturing network


DUBLIN, December 30, 2021 / PRNewswire / – The report, “EU COVID-19 Vaccines and Therapeutics Insights, Trends, and Growth Opportunities” was added to to offer.

This research service provides critical insights into the COVID-19 vaccines and therapeutics market in the European Union and the United Kingdom. The report analyzes COVID-19 vaccines and therapeutics in development and looks at supply chain considerations and requirements to manage sales. It is important that the study identifies actionable growth opportunities for industry participants.

Like The United States, The European Union has been criticized for vaccine nationalism, but is taking steps to promote global access to vaccines. It launched the Team Europe initiative to improve manufacturing and access to vaccines, medicines and health technologies Africa.

Initiatives like the EU digital vaccination pass and the UK NHS COVID Pass app will help Europe in reopening safely and overcoming worrying COVID-19 variants to some extent. Although vaccinations are advancing rapidly, political and religious situations, availability and access to vaccines, and vaccination reluctance, especially among younger populations, are factors that will determine the further course of the campaigns.

The low vaccination rate in central and Eastern Europe (CEE) is fueling another COVID-19 surge and causing a health crisis in Bulgaria, Romania and Latvia.

Topics covered include:

  • Analysis of COVID-19 vaccines and therapeutics
  • Vaccine manufacturers‘ strategies to expand their global production network
  • Introduction of the COVID-19 vaccination
  • The role of digital technology in the fight against COVID-19
  • The growth opportunity universe

Key topics covered:

1. Strategic imperatives

2. Vaccine and Therapeutic Highlights

  • Regional effects of COVID-19 vaccinations

3. Analysis of growth opportunities

  • Scope of analysis
  • Growth drivers for recovery from COVID-19 pandemic
  • Growth barriers to recovery from the COVID-19 pandemic

4. Global R&D Landscape for COVID-19 Vaccines

  • COVID-19 vaccine pipeline analysis
  • Overview of the main authorized COVID-19 vaccines worldwide
  • Selected vaccine candidates in phase III

5. Global therapeutic R&D landscape for COVID-19

  • Small key molecules in late development (antivirals and immunomodulators)
  • Key late-stage mAbs
  • Snapshot of EU COVID-19 therapeutics

6. Vaccine manufacturers’ strategies to expand their global network

  • Pfizer / BioNTech vaccines
  • Modern
  • J&J
  • Oxford / AZ
  • Novavax

7. Introduction of COVID-19 vaccination in the EU

  • Capacity secured
  • Distribution of COVID-19 vaccine doses by manufacturer
  • Percentage of adults fully vaccinated against COVID-19
  • COVID-19 vaccine doses administered in selected countries
  • Germany – Approaching the 70% milestone of the first dose
  • France – More than 70% of the population fully vaccinated
  • Italy – Reached the 70% milestone for the first dose
  • United Kingdom – First European country to hit the 70% first dose milestone
  • Behind the successful rollout in the UK
  • DHL Express hub and gateway model

8. Role of digital technology in the fight against COVID-19

  • Digital technology platforms that enable data management, vaccination and recovery from COVID-19
  • EU-COVID-19 certificate / health passport
  • IBM Digital Health Pass

9. Growth Opportunity Universe

  • Growth Chance 1 – Additional and booster doses for declining immunity and emerging virus variants
  • Growth Opportunity 2 – Strengthening Domestic Manufacturing for the World’s Leading Supply of COVID-19 Vaccines
  • Growth opportunity 3 – Global standard solution for recognition and verification of the COVID-19 health passport of individual countries

Mentioned companies

  • AstraZeneca
  • BioNTech
  • DHL
  • IBM
  • J&J
  • Modern
  • Novavax
  • Oxford
  • Pfizer

Please visit for more information on this report

Via is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, top companies, new products and the latest trends.

Media contact:

Research and Markets
Laura wood, Senior manager
[email protected]

For EST office hours, call + 1-917-300-0470. on
For US / CAN toll free call + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900. on

US Fax: 646-607-1904
Fax (outside the US): + 353-1-481-1716

SOURCE Research and Markets

similar links


Comments are closed.